Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-26T09:08:18.302Z Has data issue: false hasContentIssue false
  • English
  • Français

Drug utilization of paliperidone in adolescent schizophrenia patients: A retrospective cohort study in China

Published online by Cambridge University Press:  13 August 2021

S. Dong ,
T. Zhang ,
T. Wu ,
L. Zhang ,
H. Sun ,
W. Dong  and
H. Wang
S. Dong*
Affiliation:
Epidemiology, Janssen Research and Development, China, Shanghai, China
T. Zhang
Affiliation:
Epidemiology, Janssen Research and Development, Beijing, China
T. Wu
Affiliation:
Epidemiology, Janssen Research and Development, Beijing, China
L. Zhang
Affiliation:
Medical Affairs, Janssen Research and Development, China, Shanghai, China
H. Sun
Affiliation:
Medical Affairs, Janssen Research and Development, China, Shanghai, China
W. Dong
Affiliation:
Peking University The Sixth Hospital, Institute Of Mental Health; National Clinical Research Center For Mental Health Disorders & Key Laboratory Of Mental Health, Ministry Of Health, Peking University, Peking University the Sixth Hospital, Beijing, China
H. Wang
Affiliation:
Xijing Hospital, the Fourth Military Medical University, Xi’an, China, xian, China
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

In China, the indications of paliperidone extended in schizophrenia adolescents (12-17 years) was approved by National Medical Products Administration (NMPA) in 2017. But, the utilization of paliperidone in this group needs to be further investigated.

Objectives

To assess paliperidone utilization in schizophrenia adolescents.

Methods

The study employed the electronic medical records (EMRs) database from a psychiatry specialized hospital (PH) and a general hospital (GH), respectively. General information, including birth date, gender, visit date, diagnosis (inpatient and outpatient) with ICD-10 coding, drug characterize, prescription date and dosage, was de-identified and standardized for analysis. Schizophrenia adolescents (ICD-10: F20.x) received at least one prescription of paliperidone between 2018 and 2019 were included in this study. Index date was defined as the date of first identified paliperidone prescription. The patients were followed up until the end of 2019 with the last record, or upon reaching 18 years. The database was analyzed based on days of supply, administration frequency, and daily dose.

Results

Overall, 112 and 117 eligible patients were included in the present study from PH and GH, respectively. The median drug supply was 179.0 days and 44.0 days, respectively, during which median number of prescriptions patients received was 6.0 and 3.0. Paliperidone was mostly initiated alone (57.1% and 88.9%) with frequency of once daily (97.3% and 88.9%), and the median of average daily dose during follow-up was 5.7 mg/day and 6.0 mg/day, respectively.

Conclusions

The duration of paliperidone usage was very different in two hospitals, but the dosages in both hospitals were generally agreed with prescribing information.

Keywords

Drug Utilizationpaliperidoneschizophréniaadolescent
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S511
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.